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Since 1997 the US National Institute on Drug Abuse has advocated a brain disease model of 
addiction (BDMA). We assess the strength of evidence for the BDMA in animals, neuroimaging 
studies of people with addiction, and current research on the role of genetics in addiction. We 
critically assess claims about the medical and social beneﬁts of use of the BDMA because the social 
implications are often implied as a reason to accept this model. Furthermore, we argue that the 
BDMA is not supported by animal and neuroimaging evidence to the extent its advocates suggest; it 
has not helped to deliver more eﬀective treatments for addiction; and its eﬀect on public policies 
toward drugs and people with addiction has been modest. The focus of the BDMA is on disordered 
neurobiology in a minority of severely addicted individuals, which undermines the implementation 
of eﬀective and cost-eﬀective policies at the population level to discourage people from smoking 
tobacco and drinking heavily. The pursuit of high technology direct brain interventions to cure 
addiction when most individuals with addiction do not have access to eﬀective psychosocial and 
drug treatments is questionable. 
  
Introduction 
In 1997, Alan Leshner, then Director of the US National Institute on Drug Abuse (NIDA), published a 
report 1 in Science in which he argued that addiction was best conceptualised as a chronic, 
relapsing, brain disease. Although Leshner acknowledged that drug use was initially voluntary, he 
argued on the basis of animal models that chronic drug use ﬂicked a neurochemical switch in the 
brain, making it very diﬃcult for people addicted to drugs to stop using them, which would explain 
the high incidence of relapse in people treated for addiction. Researchers at NIDA have since done a 
substantial number of neuroimaging studies on people with drug addiction and they argue that the 
results explain how chronic drug use hijacks the brain’s reward systems. 2 
Proponents of the brain disease model of addiction (BDMA) have been very inﬂuential in setting the 
funding priorities of NIDA, and by extension the bulk of publically supported research on addiction. 
In 1998, Leshner testiﬁed that NIDA supports more than 85% of the world’s research on drug abuse 
and addiction. 3 The American Society of Addiction Medicine has deﬁned addiction as a “primary, 
chronic disease of brain reward, motivation, memory, and related circuitry”. 4 In July, 2014, newly 
appointed Acting Director of US National Drug Control Policy, Michael Botticelli, launched a 
reformist strategy nationally, claiming decades of research have demonstrated that addiction is a 
brain disorder—one that can be prevented and treated. 5 The BDMA has also been widely discussed 
in leading scientiﬁc research journals 3,6 and most recently in a positive editorial in Nature. 7 
In the USA, proponents of the BDMA have argued that it will help to deliver more eﬀective medical 
treatments for addiction with the cost covered by health insurance, making treatment more 
accessible for people with addictions. 1,2,6 An increased acceptance of the BDMA is also predicted 
to reduce the stigma associated with drug 
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addiction by replacing the commonly held notion that people with drug addiction are weak or bad 
with a more scientiﬁc viewpoint that depicts them as having a brain disease that needs medical 
treatment. 
In this Personal View, we critically assess the scientiﬁc evidence for the BDMA reported in leading 
general scientiﬁc journals and the extent of the social beneﬁts that advocates of the BDMA claim it 
has produced, or is likely to produce, with its widespread acceptance among clinicians, policy 
makers, and the public. The BDMA is not co-extensive with neuroscience-based explanations of 
addiction. This review is not intended as a critique of all neuroscience research on addiction. We 
focus instead on the popular simpliﬁcation of work in this specialty that has had a major inﬂuence on 
popular discourse on addiction in scientiﬁc journals and mainstream media. 
 
Evidence for the BDMA 
Studies of animal models have had a central role in the development of the BDMA by providing 
insights into the eﬀects that chronic drug administration has on brain processes.8,9 These studies 
show that rats and other animals will self-administer psychoactive drugs at high frequencies (eg, by 
pressing a lever); 9,10 the drugs that animals self-administer are similarly addictive in humans; and 
self-administration of drugs is decreased by electrical stimulation of the so-called reward centres in 
the brain.9 The use of animal models has enabled researchers to identify the neural circuitry on 
which the most addictive drugs act, namely the mesolimbic brain reward system, including the 
ventral striatum, nucleus accumbens, amygdala, and frontal cortices. Dopamine signalling has a key 
role in this system. 11,12 
Animal models reproduce some key features of human addiction.13 Animals provided with free 
access to drugs often increase the frequency and amount of drugs they self-administer and work 
harder to obtain drugs, mimicking the development of tolerance and dose escalation in humans. 
Furthermore, they will continue to self-administer drugs associated with aversive stimuli (eg, 
electrical foot shock). Animals will rapidly resume self-administration when they are given painful 
stimuli, are exposed to cues associated with the drug, or primed with a dose of the drug. 8,12,14 
Results from animal studies are supported by the results of neuroimaging studies on the role of 
dopamine activation in the reward circuits in so-called normal and addicted human brains.6,15,16 
Neuroimaging studies have shown dopamine-mediated changes in cortical areas correlate with 
impaired decision making and poor impulse control. 17,18 The persistence of many of these brain 
changes in people with addiction after long periods of abstinence is used to explain the high 
incidence of relapse in people treated for addiction. 19 
Further support for the BDMA is provided by genetic research on addiction. Twin-studies indicate 
that genetic factors substantially contribute to the risk of development of alcohol, nicotine, and 
cannabis addiction .20,21 Estimates of the heritability of alcohol, nicotine, and cannabis dependence 
range from 40% to 60%.21 Large-scale genome- wide association studies show correlations between 
the presence of genetic markers and the risk of development of addiction. Risk alleles that aﬀect 
drug metabolism and the eﬀect that drugs have on the mesolimbic reward system have been 
identiﬁed, which suggests that addiction is the outcome of the eﬀects of chronic drug use on the 
brains of genetically susceptible individuals. 20,21 
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A critical examination of the evidence for BDMA 
Is addiction a chronic disorder? 
Critics of BDMA contest claims by its proponents that addiction is a chronic relapsing disorder and 
cite epidemiological evidence that most people with addiction recover without treatment. 22–24 
Heyman 23 points out that most people with diagnosed drug dependence in epidemiological surveys 
are not drug dependent at the time of their interview, and have ceased recreational drug use years 
previously, usually in the absence of treatment. Similarly, a high incidence of recovery was shown in 
follow-up studies of heroin-addicted US veterans of the Vietnam war. 25 
Critics also argue that it is diﬃcult to reconcile a strong form of the BDMA with evidence that people 
addicted to recreational drugs respond to small changes in their personal situations. 22,23 For 
example, the receipt of small ﬁnancial rewards or the avoidance of 24 h in jail by providing clean 
urine samples, substantially decreased drug use in people with drug addiction. 23,26 The 
responsiveness of drug users to these small incentives is hard to reconcile with the claim that drug 
use is a compulsive behaviour over which people who are addicted have little or no control. 22,23 
The BDMA can be reconciled with the high incidence of recovery from addiction if we allow for the 
fact that addiction varies in severity, measured with common diagnostic criteria, and that less severe 
addictive disorders are the most common and people with this type of disorder the most likely to 
recover without treatment.27 Chronic addiction occurs in a minority of people with addiction, 
especially those who use drugs into their early 30s despite accumulated adverse health eﬀects and 
social consequences. Chronic drug users seem a better ﬁt to the picture of addiction as a relapsing 
brain disease because they are the group most likely to seek treatment after failure to control their 
drug use and to have changes in brain function that might have a role in their continued drug use.24 
This modiﬁed BDMA applies to a few drug users who meet the diagnostic criteria for addiction in 
epidemiological studies. Advocates of the BDMA who accept this weaker form of the model cannot 
equate the lifetime prevalence of addictive disorders with the prevalence of the severe and chronic 
addictive disorders, which exemplify the BDMA. A critical analysis of research on the neurobiology of 
addiction, however, raises doubts about how compelling the BMDA is in terms of providing an 
explanation of the few people with severe, chronic addiction. 
 
Animal models of addiction 
Addictive behavioural patterns are not invariably the outcome of chronic self-administration of 
drugs in animals. Popular accounts of these studies underplay the extent to which the results 
depend on speciﬁcally bred strains of rats and the conditions in which the animals are housed.28 
Rats taught to self-administer opiates under standard conditions for addiction behaviour do not 
display this behaviour when housed in more natural conditions (eg, with litter mates). 29 Rats 
housed in enriched environments might have diﬀerent patterns of drug self-administration and 
reinstatement (a return or relapse to addictive patterns of drug self-administration following a 
stressful event or the consumption of a small quantity of the addictive drug). 28 Rats trained to self- 
administer drugs will abstain when given a choice of natural rewards such as food or pair bonding.28 
Animal models of addiction reveal little about the incidence of recovery from addiction in the 
absence of speciﬁc interventions. 24 For example, Koob and LeMoal’s analysis12 of the analogies 
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between animal models and the so-called stages of human addiction does not include recovery. 
Their implicit assumption is that once addicted an animal (or a person) will remain so unless treated, 
and if treated will be at high risk of relapse. This viewpoint might seem too pessimistic with respect 
to the epidemiological evidence reviewed above. 
 
Genetics of addiction 
Addiction is not a disorder conﬁned to people who carry the small number of so-called addiction 
genes. A large number of alleles are involved in the genetic susceptibility to addiction and 
individually these alleles might very weakly predict a risk of addiction.20,21,30 Scores for the genetic 
risk of addiction based on diﬀerent combinations of many risk alleles do predict the risk of addiction 
but do so no better than a simple family history (eg, number of parents who smoke).31 Generally, 
genetic prediction of the risk of disease (even with whole-genome sequencing data) is unlikely to be 
informative for most people who have a so-called average risk of developing an addiction disorder. 
30,32 
 
Human neuroimaging studies 
Neuroimaging studies of addiction 33 show people with addiction diﬀer signiﬁcantly from people 
without addiction more than they should, in view of the studies’ sample sizes and the sizes of the 
diﬀerence between groups. 33,34 The excess of signiﬁcant results shows the eﬀect of chance in large 
numbers of comparisons of activity between brain regions or structures, the selective publication of 
positive results, and delay in publication of failures to replicate the positive results.35 In studies that 
do robustly show people with addiction diﬀer from controls, there are large overlaps in the size of 
brain structures and hypo-functionality or hyper-functionality of speciﬁc brain regions in people with 
addiction and in control groups.36 Researchers reporting results of neuroimaging studies on 
addiction37 acknowledge these limitations, but more popular accounts often do not. 
Case-control studies do not show whether addiction is a cause or a consequence of diﬀerences in 
brain structure and function or some combination of the two. 38 Patterns of brain activity on MRI in 
people with addiction diﬀer from people without addiction and do not show the use of drugs is a 
compulsion.39 The fact that decreased activity in frontal brain regions is modestly correlated with 
self- reported drug craving does not show that drug use is driven by irresistible impulses. 24 
The increasing complexity of addiction neurobiology The postulated neurobiology underlying the 
BDMA has become progressively complicated since 1997. Chronic drug use once thought to hijack 
the reward centres in the brain is now acknowledged to aﬀect brain structures involved in high-
order cognitive control of impulses. 15,40 Volkow and colleagues17,41 acknowledge the neuro- 
pharmacological complexity of addiction in that many neurotransmitter systems are implicated in 
addiction (eg, γ-aminobutyric acid, N-methyl-D-aspartate, opioid, and serotonin). The researchers 
emphasise the importance of epigenetics (changes in gene expression that in brain systems might be 
produced by chronic drug use), which they identify as a new target for drug treatments. Despite 
acknowledgment of the complex neurobiology in addiction, the simplest form of the BDMA 
continues to dominate public education materials. 42 
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Promised policy payoﬀs from the BDMA 
Improved drugs to treat addiction 
Leshner predicted the BDMA would help to develop drugs and behavioural treatments to reverse or 
compensate for the brain changes underlying addiction,1 thereby delivering more eﬀective 
treatment for addiction. New drugs to treat addiction include vaccines and implantable agonists and 
antagonists against neurotransmitters to decrease the risk of relapse; DNA tests to match patients to 
the most eﬀective treatment; drugs to modulate the stress response; drugs to modify memories of 
drug- related cues; and most recently, drugs to reverse epigenetic changes in chronic drug use. 43–
45 
The promised treatment beneﬁts associated with the BDMA have not materialised.46 Few new 
drugs have been approved for the treatment of addiction in the past two decades.47 The most 
widely used drugs in addiction (eg, methadone and nicotine replacement therapy) preceded the 
BDMA by more than 30 years. A few drugs (eg, naltrexone and varenicline) derived from research 
into the neurobiology of addiction are only modestly superior to older drugs, such as disulﬁram and 
substitution of cigarettes with non-smoked forms of nicotine, such as nicotine gum or 
patches.37,48–50 The investment of NIDA in research on vaccines against nicotine and cocaine 
dependence has produced disappointing results. 51–53 
Substantial obstacles remain to the development of eﬀective drugs to treat addiction. Many of these 
obstacles are shared with drug development in biomedicine more generally, 54 including very low 
success rates in replication of the ﬁndings of promising drug targets in basic research 55,56 and the 
low replicability of the results of small sample animal studies. 57 Few drugs showing promise in 
animal models progress to clinical trials due to unacceptable side eﬀects, whereas others fail to 
show eﬃcacy in phase 2 clinical trials. 
Special challenges exist to the development of new drugs to treat addiction. Pharmaceutical 
companies might be reluctant to invest in drug development because they doubt new drugs to treat 
addiction will be proﬁtable, in view of the limited capacity of people with addiction to pay for 
treatment, the absence or limited availability of health insurance coverage for addiction treatments 
in the USA, and regulations that prevent the clinical use of drugs with similar eﬀects to recreational 
drugs. 47 Pharmaceutical companies might fear that the stigma associated with the treatment of 
addiction will discourage other potentially more proﬁtable uses of these drugs (eg, to treat chronic 
pain).47 
 
Direct brain interventions for addiction 
Leshner’s argument that attending to the brain needs to be a core part of treatment of addiction 1 
has prompted proposals to directly intervene in the brains of people with addiction. In the early 
2000s, Koob’s work 58 was used to justify ablative neurosurgery as a treatment for heroin addiction 
in China and Russia. Deep brain stimulation (DBS) is now advocated as a more targeted and 
reversible alternative to neurosurgical ablation. 59,60 
Advocates of DBS as a treatment for addiction cite animal studies in which lesions in the 
dopaminergic 
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reward pathway have decreased self-administration of drugs. 61 Case reports of patients who have 
been treated with DBS for indications other than addiction and who have reported that their 
addictive behaviour was decreased are also cited .62 Furthermore, case reports now exist of the 
apparently successful use of DBS to treat alcohol and heroin dependence.62 
Advocates of DBS to treat addiction have argued that it will be an eﬀective and cost eﬀective way to 
reduce the economic and social costs of addiction. 60 However, the probable population-wide cost 
has been overstated to justify the high costs of the procedure (more than US$50 000 to implant a 
stimulator and $10 000 per year for maintenance). 63 If DBS is proven eﬀective, only a few people 
with addiction who are wealthy enough to aﬀord the treatment might receive it; patients with 
addiction who generate the social and economic costs that have been used to justify DBS trials are 
least likely to receive the treatment. 60 
 
Overinvestment in high risk strategies for legal drugs 
A major risk of the BDMA is that it will lead to the neglect of public health policies in favour of a 
search for biomedical treatments of people with severe addiction.64,65 This prioritisation is shown 
in the allocation of NIDA’s 2014 $1065·24 million research budget: 23·8% to epidemiology, health 
services and prevention; 41·4% to basic and clinical neuroscience research; and 16·5% to 
pharmacotherapies and the rest spent on intramural research and research support.66 
The imposition of high taxes on cigarettes, enactment of bans on advertising and restrictions on 
where people can smoke, have halved the incidence of cigarette smoking in Australia67 and the 
USA68 in the past three decades. These strategies are more eﬃcient than drug vaccines, predictive 
genetic testing, or neurosurgical interventions aimed at smokers and people at risk of smoking.64 
They are more cost-eﬀective in the prevention of addiction than the screening of whole populations 
and intervention with a few people who are at high genetic risk of addiction if they smoke 
tobacco.69 Similarly, evidence exists to support the eﬃciency of population-based strategies in the 
reduction of the societal harms of alcohol misuse.70 The eﬀectiveness of population-level 
approaches is not an argument against the provision of clinical treatment to people with addictive 
disorders. A real concern exists, however, that an overemphasis on the BDMA could undermine 
population level approaches when misused by the alcohol and tobacco industries in opposing public 
health policies. 71 
 
Illicit drug policy 
Striking diﬀerences exist in policies based on research into the neurobiology of addiction. In the USA, 
proponents of the BDMA have been mostly silent about its implications for US drug policy, arguably 
allowing the BDMA to become part of an overinvestment in law enforcement eﬀorts to decrease 
drug supply .72 
NIDA has expended substantial resources to replace the view of addiction as morally wrong with one 
of addiction as a treatable medical disorder.1,2,6 Until now there have arguably been meagre 
returns on this investment. The most positive development was the inclusion of addiction treatment 
in the Patient Protection and Aﬀordable Care Act and provision of health-care through Obamacare. 5 
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By contrast, in the UK leading addiction neuroscientists have used their research to question 
whether cannabis, 3,4-methylenedioxy-N-methylamphetamine (MDMA), and LSD should remain 
illegal. David Nutt, formerly the government’s chief drug advisor, has argued that the harms caused 
by alcohol, cannabis, cocaine, heroin, MDMA, and tobacco do not justify the diﬀerent legal status of 
these drugs.73 
The results of research into the neuroscience of addiction cannot be, and ought not to be, the 
decisive factor in setting drug policy. In democratic societies, government drug policy should come 
from the trade-oﬀ between goods and harms, such as the pleasurable eﬀects of drugs enjoyed by 
adults, the harms that drug use can cause, and the social and economic costs and beneﬁts of the 
diﬀerent ways to allow or restrict the sale and use of drugs. Ideally, these tradeoﬀs should be made 
by political representatives who are well informed about epidemiological, sociological, economic, 
and neuro- biological research on drug use and addiction. 
 
Conclusions 
Considerable scientiﬁc value exists in the research into the neurobiology and genetics of addiction, 
but this research does not justify the simpliﬁed BDMA that dominates discourse about addiction in 
the USA and, increasingly, elsewhere. Editors of Nature were mistaken in their assumption that the 
BDMA represents the consensus view in the addictions specialty,7 as shown by a letter signed by 94 
addiction researchers and clinicians (including one of the authors of this Personal View).74 
Understanding of addiction, and the policies adopted to treat and prevent problem drug use, should 
give biology its due, but no more than it is due. Chronic drug use can aﬀect brain systems in ways 
that might make cessation more diﬃcult for some people. Economic, epidemiological, and social 
scientiﬁc evidence shows that the neurobiology of addiction should not be the over-riding factor 
when formulating policies toward drug use and addiction. 
The BDMA has not helped to deliver the eﬀective treatments for addiction that were originally 
promised by Leshner and its eﬀect on public health policies toward drug addiction has been modest. 
Arguably, the advocacy of the BDMA led to overinvestment by US research agencies in biological 
interventions to cure addiction that will have little eﬀect on drug addiction as a public health issue. 
Increased access to more eﬀective treatment for addiction is a worthy aim that we support but this 
aim should not be pursued at the expense of simple, cost eﬀective, and eﬃcient population-based 
policies to discourage the whole population from smoking tobacco and drinking heavily. Nor should 
the pursuit of high technology cures distract from the task of increasing access to available 
psychosocial and drug treatments for addiction, which most people with addictive disorder are still 
unable to access. 
Our rejection of the BDMA is not intended as a defence of the moral model of addiction.6 5 We 
share many of the aspirations of those who advocate the BDMA, especially the delivery of more 
eﬀective treatment and less punitive responses to people with addiction issues. Addiction is a 
complex biological, psychological, and social disorder that needs to be addressed by various clinical 
and public health approaches.65 Research into the neuroscience of addiction has provided insights 
into the neurobiology of decision-making, motivation, and behavioural control in addiction. Chronic 
use of addictive drugs can impair cognitive and motivational processes and might partly explain why 
some people are more susceptible than others to developing an addiction. The challenge for all 
addiction researchers—including neurobiologists—is to integrate emerging insights from 
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neuroscience research with those from economics, epidemiology, sociology, psychology, and 
political science to decrease the harms caused by drug misuse and all forms of addiction. 46 
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